title: Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment.
abstract: OBJECTIVE
  Finasteride affects both prostate cancer risk and body weight. We examined whether, during 7 years of finasteride treatment, the magnitude of weight change was associated with the diagnosis of no, low-, or high-grade cancer.
  
  
  METHODS
  Data are from 10,057 participants in Prostate Cancer Prevention Trial (PCPT), a randomized trial of finasteride for primary prevention of prostate cancer. Mixed linear models were used to calculate percentage change in weight per year, controlling for demographic and health-related covariates.
  
  
  RESULTS
  Weight gain was modestly lower in the finasteride compared to placebo arms (0.14 vs. 0.16% per year, P<0.025). On the placebo arm, there was no association of weight gain with cancer outcomes. In the finasteride arm, annual weight gain among men without cancer was 0.14%, and among men with cancer ranged from 0.01% for those diagnosed with high-grade cancer following a clinical indication for biopsy (P=0.03 vs. no cancer) to 0.25% among men diagnosed with low-grade cancer at the end of the trial with no indication for biopsy (P=0.002 vs. no cancer).
  
  
  CONCLUSIONS
  In finasteride-treated men, there are significant associations between prostate cancer outcomes and weight gain, which suggest that there are common or closely related individual-level factors that affect both treatment responses. This supports the hypothesis that there are genetic characteristics and/or environmental exposures that affect finasteride outcomes which, when identified, could be used to target men most likely to benefit from finasteride treatment.
authors.affiliation: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
authors.forename: YoonJu
authors.initials: Y
authors.lastname: Song
authors.forename: Catherine
authors.initials: C
authors.lastname: Tangen
authors.forename: Phyllis
authors.initials: P
authors.lastname: Goodman
authors.forename: Howard L
authors.initials: HL
authors.lastname: Parnes
authors.forename: M Scott
authors.initials: MS
authors.lastname: Lucia
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
authors.forename: Alan R
authors.initials: AR
authors.lastname: Kristal
mesh_terms: D000368:Aged; D001706:Biopsy; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000235:genetics / Q000517:prevention & control*; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride